KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Receivables - Net (2016 - 2025)

Historic Receivables - Net for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $39.5 million.

  • NovoCure's Receivables - Net fell 4109.75% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year decrease of 4109.75%. This contributed to the annual value of $35.1 million for FY2024, which is 5461.92% up from last year.
  • Per NovoCure's latest filing, its Receivables - Net stood at $39.5 million for Q3 2025, which was down 4109.75% from $89.9 million recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Receivables - Net peaked at $101.0 million during Q1 2022, and registered a low of $17.0 million during Q4 2021.
  • In the last 5 years, NovoCure's Receivables - Net had a median value of $74.8 million in 2023 and averaged $66.9 million.
  • In the last 5 years, NovoCure's Receivables - Net surged by 40667.25% in 2022 and then tumbled by 7371.12% in 2023.
  • NovoCure's Receivables - Net (Quarter) stood at $17.0 million in 2021, then soared by 406.67% to $86.3 million in 2022, then tumbled by 73.71% to $22.7 million in 2023, then soared by 54.62% to $35.1 million in 2024, then rose by 12.65% to $39.5 million in 2025.
  • Its Receivables - Net was $39.5 million in Q3 2025, compared to $89.9 million in Q2 2025 and $84.5 million in Q1 2025.